ID

31535

Descripción

This Trial is a Safety and Feasibility Study of Combination of State of the Art Chemoimmunotherapy, Intensive Central Nervous System Prophylaxis and Scrotal Irradiation to Treat Primary Testicular Diffuse Large B-cell Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT00945724

Link

https://clinicaltrials.gov/show/NCT00945724

Palabras clave

Versiones (1)
  1. 2/9/18 2/9/18 -
Titular de derechos de autor

See clinicaltrials.gov

Subido en

2 de septiembre de 2018

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Primary Testicular Diffuse Large B-cell Lymphoma NCT00945724

Inglés

Eligibility Primary Testicular Diffuse Large B-cell Lymphoma NCT00945724

1 formularios  
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. patients with primary testicular lymphoma at diagnosis. histological subtype included into the study is only diffuse large b cell lymphoma (attachment 2: who classification of lymphoma).
Descripción

Primary testicular lymphoma | Diffuse Large B-Cell Lymphoma WHO tumor classification

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0349644
UMLS CUI [2,1]
C0079744
UMLS CUI [2,2]
C1301142
2. orchiectomy is mandatory, before enrolment of the patient into the study.
Descripción

Orchiectomy mandatory

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0029189
UMLS CUI [1,2]
C1514873
3. orchiectomy should be performed within 2 months before study entry.
Descripción

Orchiectomy Recently

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0029189
UMLS CUI [1,2]
C0332185
4. age 18-80
Descripción

Age

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0001779
5. untreated patients
Descripción

Patients untreated

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0030705
UMLS CUI [1,2]
C0332155
6. ann arbor stage ie and iie. bilateral testicular involvement at presentation will not be considered stage iv. these patients may be included into the study and the final ann arbor stage (i or ii) will be determined by the extent of nodal disease.
Descripción

Ann Arbor lymphoma staging system | Testicular Involvement Bilateral

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0432516
UMLS CUI [2,1]
C4053942
UMLS CUI [2,2]
C0238767
7. bidimensionally measurable or evaluable disease. patients who have had all disease removed by surgery are eligible.
Descripción

Measurable Disease 2-Dimensional | Evaluable Disease | Excision Disease All

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1513041
UMLS CUI [1,2]
C1705052
UMLS CUI [2]
C1516986
UMLS CUI [3,1]
C0728940
UMLS CUI [3,2]
C0012634
UMLS CUI [3,3]
C0444868
8. adequate haematological counts: anc > 1.0 x 109/l and plts count > 75 x 109/l
Descripción

Hematologic function | Absolute neutrophil count | Platelet Count measurement

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0221130
UMLS CUI [2]
C0948762
UMLS CUI [3]
C0032181
9. cardiac ejection fraction ≥ 45% by muga scan or echocardiography
Descripción

Cardiac ejection fraction MUGA scan | Cardiac ejection fraction Echocardiography

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0232174
UMLS CUI [1,2]
C0521317
UMLS CUI [2,1]
C0232174
UMLS CUI [2,2]
C0013516
10. non peripheral neuropathy or any active non-neoplastic cns disease.
Descripción

Neuropathy | Exception Peripheral Neuropathy | Non-Neoplastic Central Nervous System Disorder

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0442874
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0031117
UMLS CUI [3]
C1335000
11. no other major life-threatening illnesses that may preclude chemotherapy
Descripción

Life threatening illness Absent | Life threatening illness Excludes Chemotherapy

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C3846017
UMLS CUI [1,2]
C0332197
UMLS CUI [2,1]
C3846017
UMLS CUI [2,2]
C0332196
UMLS CUI [2,3]
C0392920
12. conjugated bilirubin ≤ 2 x uln.
Descripción

Serum conjugated bilirubin measurement

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1278038
13. alkaline phosphatase and transaminases ≤ 2 x uln.
Descripción

Alkaline phosphatase measurement | Transaminase Assay

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0201850
UMLS CUI [2]
C0919834
14. creatinine clearances ≥ 45 ml/min.
Descripción

Creatinine clearance measurement

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0373595
15. hiv negativity
Descripción

HIV negative

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0481430
16. hbv negativity or patients with hbvcab +, hbsag -, hbs ab+/- with hbv-dna negative
Descripción

Hepatitis B Virus Negative | HBcAb Positive | Hepatitis B surface antigen negative | Hepatitis B Virus Surface Antibody Positive | Hepatitis B Virus Surface Antibody Negative | Hbv DNA Test Negative

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0019169
UMLS CUI [1,2]
C1513916
UMLS CUI [2,1]
C3702086
UMLS CUI [2,2]
C1514241
UMLS CUI [3]
C0919711
UMLS CUI [4,1]
C0369334
UMLS CUI [4,2]
C1514241
UMLS CUI [5,1]
C0369334
UMLS CUI [5,2]
C1513916
UMLS CUI [6,1]
C1256114
UMLS CUI [6,2]
C1513916
17. hcv negativity with the exception of patients with no signs of active chronic hepatitis histologically confirmed
Descripción

Hepatitis C virus Negative | Exception Absence Signs Chronic Hepatitis

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0220847
UMLS CUI [1,2]
C1513916
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0332197
UMLS CUI [2,3]
C0311392
UMLS CUI [2,4]
C0019189
18. life expectancy > 6 months.
Descripción

Life Expectancy

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0023671
19. performance status < 2 according to ecog scale.
Descripción

ECOG performance status

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1520224
20. no psychiatric illness that precludes understanding concepts of the trial or signing informed consent
Descripción

Mental disorders Absent

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0004936
UMLS CUI [1,2]
C0332197
21. written informed consent
Descripción

Informed Consent

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. has known or suspected hypersensitivity or intolerance to rituximab
Descripción

Hypersensitivity Rituximab | Intolerance to Rituximab | Hypersensitivity Suspected Rituximab | Intolerance Suspected Rituximab

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0393022
UMLS CUI [2,1]
C1744706
UMLS CUI [2,2]
C0393022
UMLS CUI [3,1]
C0020517
UMLS CUI [3,2]
C0750491
UMLS CUI [3,3]
C0393022
UMLS CUI [4,1]
C1744706
UMLS CUI [4,2]
C0750491
UMLS CUI [4,3]
C0393022
2. history of clinically relevant liver or renal insufficiency; significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, rheumatologic, hematologic, psychiatric, or metabolic disturbances
Descripción

Hepatic Insufficiency | Renal Insufficiency | Heart Diseases | Vascular Diseases | Lung diseases | Gastrointestinal Diseases | Endocrine System Diseases | Nervous system disorder | Rheumatism | Hematological Disease | Mental disorders | Metabolic Diseases

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1306571
UMLS CUI [2]
C1565489
UMLS CUI [3]
C0018799
UMLS CUI [4]
C0042373
UMLS CUI [5]
C0024115
UMLS CUI [6]
C0017178
UMLS CUI [7]
C0014130
UMLS CUI [8]
C0027765
UMLS CUI [9]
C0035435
UMLS CUI [10]
C0018939
UMLS CUI [11]
C0004936
UMLS CUI [12]
C0025517
3. uncontrolled diabetes (if receiving antidiabetic agents, subjects must be on a stable dose for at least 3 months before first dose of study drug)
Descripción

Diabetic - poor control | Antidiabetics Dose Stable

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0421258
UMLS CUI [2,1]
C0935929
UMLS CUI [2,2]
C0178602
UMLS CUI [2,3]
C0205360
4. uncontrolled or severe cardiovascular disease including myocardial infarction within 6 months of enrollment, new york heart association (nyha) class iii or iv heart failure (attachment 5, nyha classification of cardiac disease), uncontrolled angina, clinically significant pericardial disease, or cardiac amyloidosis
Descripción

Cardiovascular Disease Uncontrolled | Cardiovascular Disease Severe | Myocardial Infarction | Heart failure New York Heart Association Classification | Angina Pectoris Uncontrolled | Disorder of pericardium | Cardiac amyloidosis

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0007222
UMLS CUI [1,2]
C0205318
UMLS CUI [2,1]
C0007222
UMLS CUI [2,2]
C0205082
UMLS CUI [3]
C0027051
UMLS CUI [4,1]
C0018801
UMLS CUI [4,2]
C1275491
UMLS CUI [5,1]
C0002962
UMLS CUI [5,2]
C0205318
UMLS CUI [6]
C0265122
UMLS CUI [7]
C0268407
5. history of clinically relevant hypotension
Descripción

Hypotension

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0020649
6. cns involvement (meningeal and/or brain involvement by lymphoma)
Descripción

Central Nervous System Involvement | Meninges Involvement with Lymphoma | Brain Involvement with Lymphoma

Tipo de datos

boolean

Alias
UMLS CUI [1]
C4050309
UMLS CUI [2,1]
C0025285
UMLS CUI [2,2]
C1314939
UMLS CUI [2,3]
C0024299
UMLS CUI [3,1]
C0006104
UMLS CUI [3,2]
C1314939
UMLS CUI [3,3]
C0024299
7. evolving malignancy within 3 years with the exception of localized non-melanomatous skin cancer
Descripción

Malignant Neoplasms Evolving | Exception Skin carcinoma Localized

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0006826
UMLS CUI [1,2]
C0332253
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0699893
UMLS CUI [2,3]
C0392752
8. hiv positivity
Descripción

HIV Seropositivity

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0019699
9. hbv positivity with the exception of patients with hbvcab +, hbsag -, hbs ab+/- with hbv-dna negative
Descripción

Hepatitis B virus test positive | Exception HBcAb Positive | Exception Hepatitis B surface antigen negative | Exception Hepatitis B Virus Surface Antibody Positive | Exception Hepatitis B Virus Surface Antibody Negative | Exception Hbv DNA Test Negative

Tipo de datos

boolean

Alias
UMLS CUI [1]
C2748184
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C3702086
UMLS CUI [2,3]
C1514241
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0919711
UMLS CUI [4,1]
C1705847
UMLS CUI [4,2]
C0369334
UMLS CUI [4,3]
C1514241
UMLS CUI [5,1]
C1705847
UMLS CUI [5,2]
C0369334
UMLS CUI [5,3]
C1513916
UMLS CUI [6,1]
C1705847
UMLS CUI [6,2]
C1256114
UMLS CUI [6,3]
C1513916
10. hcv positivity with the exception of patients with no signs of active chronic hepatitis histologically confirmed
Descripción

Hepatitis C Virus Positive | Exception Absence Signs Chronic Hepatitis

Tipo de datos

boolean

Alias
UMLS CUI [1]
C4330254
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0332197
UMLS CUI [2,3]
C0311392
UMLS CUI [2,4]
C0019189
11. active opportunistic infection
Descripción

Opportunistic Infections

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0029118
12. receipt of extensive radiation therapy, systemic chemotherapy, or other antineoplastic therapy
Descripción

Therapeutic radiology procedure Extensive | Systemic Chemotherapy | Cancer treatment

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1522449
UMLS CUI [1,2]
C0205231
UMLS CUI [2]
C1883256
UMLS CUI [3]
C0920425
13. exposure to rituximab prior study entry
Descripción

Exposure to Rituximab

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0332157
UMLS CUI [1,2]
C0393022
14. have received an experimental drug or used an experimental medical device within 4 weeks before the planned start of treatment. concurrent participation in non-treatment studies is allowed, if it will not interfere with participation in this study.
Descripción

Investigational New Drugs | Investigational Medical Device

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0013230
UMLS CUI [2]
C2346570
15. any other co-existing medical or psychological condition that would preclude participation in the study or compromise ability to give informed consent
Descripción

Comorbidity Study Subject Participation Status Excluded | Comorbidity compromises Informed Consent | Mental condition Study Subject Participation Status Excluded | Mental condition compromises Informed Consent

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0009488
UMLS CUI [1,2]
C2348568
UMLS CUI [1,3]
C0332196
UMLS CUI [2,1]
C0009488
UMLS CUI [2,2]
C2945640
UMLS CUI [2,3]
C0021430
UMLS CUI [3,1]
C3840291
UMLS CUI [3,2]
C2348568
UMLS CUI [3,3]
C0332196
UMLS CUI [4,1]
C3840291
UMLS CUI [4,2]
C2945640
UMLS CUI [4,3]
C0021430
Volver a la parte superior de la página

Similar models

Eligibility Primary Testicular Diffuse Large B-cell Lymphoma NCT00945724

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
Primary testicular lymphoma | Diffuse Large B-Cell Lymphoma WHO tumor classification
Item
1. patients with primary testicular lymphoma at diagnosis. histological subtype included into the study is only diffuse large b cell lymphoma (attachment 2: who classification of lymphoma).
boolean
C0349644 (UMLS CUI [1])
C0079744 (UMLS CUI [2,1])
C1301142 (UMLS CUI [2,2])
Orchiectomy mandatory
Item
2. orchiectomy is mandatory, before enrolment of the patient into the study.
boolean
C0029189 (UMLS CUI [1,1])
C1514873 (UMLS CUI [1,2])
Orchiectomy Recently
Item
3. orchiectomy should be performed within 2 months before study entry.
boolean
C0029189 (UMLS CUI [1,1])
C0332185 (UMLS CUI [1,2])
Age
Item
4. age 18-80
boolean
C0001779 (UMLS CUI [1])
Patients untreated
Item
5. untreated patients
boolean
C0030705 (UMLS CUI [1,1])
C0332155 (UMLS CUI [1,2])
Ann Arbor lymphoma staging system | Testicular Involvement Bilateral
Item
6. ann arbor stage ie and iie. bilateral testicular involvement at presentation will not be considered stage iv. these patients may be included into the study and the final ann arbor stage (i or ii) will be determined by the extent of nodal disease.
boolean
C0432516 (UMLS CUI [1])
C4053942 (UMLS CUI [2,1])
C0238767 (UMLS CUI [2,2])
Measurable Disease 2-Dimensional | Evaluable Disease | Excision Disease All
Item
7. bidimensionally measurable or evaluable disease. patients who have had all disease removed by surgery are eligible.
boolean
C1513041 (UMLS CUI [1,1])
C1705052 (UMLS CUI [1,2])
C1516986 (UMLS CUI [2])
C0728940 (UMLS CUI [3,1])
C0012634 (UMLS CUI [3,2])
C0444868 (UMLS CUI [3,3])
Hematologic function | Absolute neutrophil count | Platelet Count measurement
Item
8. adequate haematological counts: anc > 1.0 x 109/l and plts count > 75 x 109/l
boolean
C0221130 (UMLS CUI [1])
C0948762 (UMLS CUI [2])
C0032181 (UMLS CUI [3])
Cardiac ejection fraction MUGA scan | Cardiac ejection fraction Echocardiography
Item
9. cardiac ejection fraction ≥ 45% by muga scan or echocardiography
boolean
C0232174 (UMLS CUI [1,1])
C0521317 (UMLS CUI [1,2])
C0232174 (UMLS CUI [2,1])
C0013516 (UMLS CUI [2,2])
Neuropathy | Exception Peripheral Neuropathy | Non-Neoplastic Central Nervous System Disorder
Item
10. non peripheral neuropathy or any active non-neoplastic cns disease.
boolean
C0442874 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0031117 (UMLS CUI [2,2])
C1335000 (UMLS CUI [3])
Life threatening illness Absent | Life threatening illness Excludes Chemotherapy
Item
11. no other major life-threatening illnesses that may preclude chemotherapy
boolean
C3846017 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
C3846017 (UMLS CUI [2,1])
C0332196 (UMLS CUI [2,2])
C0392920 (UMLS CUI [2,3])
Serum conjugated bilirubin measurement
Item
12. conjugated bilirubin ≤ 2 x uln.
boolean
C1278038 (UMLS CUI [1])
Alkaline phosphatase measurement | Transaminase Assay
Item
13. alkaline phosphatase and transaminases ≤ 2 x uln.
boolean
C0201850 (UMLS CUI [1])
C0919834 (UMLS CUI [2])
Creatinine clearance measurement
Item
14. creatinine clearances ≥ 45 ml/min.
boolean
C0373595 (UMLS CUI [1])
HIV negative
Item
15. hiv negativity
boolean
C0481430 (UMLS CUI [1])
Hepatitis B Virus Negative | HBcAb Positive | Hepatitis B surface antigen negative | Hepatitis B Virus Surface Antibody Positive | Hepatitis B Virus Surface Antibody Negative | Hbv DNA Test Negative
Item
16. hbv negativity or patients with hbvcab +, hbsag -, hbs ab+/- with hbv-dna negative
boolean
C0019169 (UMLS CUI [1,1])
C1513916 (UMLS CUI [1,2])
C3702086 (UMLS CUI [2,1])
C1514241 (UMLS CUI [2,2])
C0919711 (UMLS CUI [3])
C0369334 (UMLS CUI [4,1])
C1514241 (UMLS CUI [4,2])
C0369334 (UMLS CUI [5,1])
C1513916 (UMLS CUI [5,2])
C1256114 (UMLS CUI [6,1])
C1513916 (UMLS CUI [6,2])
Hepatitis C virus Negative | Exception Absence Signs Chronic Hepatitis
Item
17. hcv negativity with the exception of patients with no signs of active chronic hepatitis histologically confirmed
boolean
C0220847 (UMLS CUI [1,1])
C1513916 (UMLS CUI [1,2])
C1705847 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
C0311392 (UMLS CUI [2,3])
C0019189 (UMLS CUI [2,4])
Life Expectancy
Item
18. life expectancy > 6 months.
boolean
C0023671 (UMLS CUI [1])
ECOG performance status
Item
19. performance status < 2 according to ecog scale.
boolean
C1520224 (UMLS CUI [1])
Mental disorders Absent
Item
20. no psychiatric illness that precludes understanding concepts of the trial or signing informed consent
boolean
C0004936 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
Informed Consent
Item
21. written informed consent
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Hypersensitivity Rituximab | Intolerance to Rituximab | Hypersensitivity Suspected Rituximab | Intolerance Suspected Rituximab
Item
1. has known or suspected hypersensitivity or intolerance to rituximab
boolean
C0020517 (UMLS CUI [1,1])
C0393022 (UMLS CUI [1,2])
C1744706 (UMLS CUI [2,1])
C0393022 (UMLS CUI [2,2])
C0020517 (UMLS CUI [3,1])
C0750491 (UMLS CUI [3,2])
C0393022 (UMLS CUI [3,3])
C1744706 (UMLS CUI [4,1])
C0750491 (UMLS CUI [4,2])
C0393022 (UMLS CUI [4,3])
Hepatic Insufficiency | Renal Insufficiency | Heart Diseases | Vascular Diseases | Lung diseases | Gastrointestinal Diseases | Endocrine System Diseases | Nervous system disorder | Rheumatism | Hematological Disease | Mental disorders | Metabolic Diseases
Item
2. history of clinically relevant liver or renal insufficiency; significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, rheumatologic, hematologic, psychiatric, or metabolic disturbances
boolean
C1306571 (UMLS CUI [1])
C1565489 (UMLS CUI [2])
C0018799 (UMLS CUI [3])
C0042373 (UMLS CUI [4])
C0024115 (UMLS CUI [5])
C0017178 (UMLS CUI [6])
C0014130 (UMLS CUI [7])
C0027765 (UMLS CUI [8])
C0035435 (UMLS CUI [9])
C0018939 (UMLS CUI [10])
C0004936 (UMLS CUI [11])
C0025517 (UMLS CUI [12])
Diabetic - poor control | Antidiabetics Dose Stable
Item
3. uncontrolled diabetes (if receiving antidiabetic agents, subjects must be on a stable dose for at least 3 months before first dose of study drug)
boolean
C0421258 (UMLS CUI [1])
C0935929 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C0205360 (UMLS CUI [2,3])
Cardiovascular Disease Uncontrolled | Cardiovascular Disease Severe | Myocardial Infarction | Heart failure New York Heart Association Classification | Angina Pectoris Uncontrolled | Disorder of pericardium | Cardiac amyloidosis
Item
4. uncontrolled or severe cardiovascular disease including myocardial infarction within 6 months of enrollment, new york heart association (nyha) class iii or iv heart failure (attachment 5, nyha classification of cardiac disease), uncontrolled angina, clinically significant pericardial disease, or cardiac amyloidosis
boolean
C0007222 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
C0007222 (UMLS CUI [2,1])
C0205082 (UMLS CUI [2,2])
C0027051 (UMLS CUI [3])
C0018801 (UMLS CUI [4,1])
C1275491 (UMLS CUI [4,2])
C0002962 (UMLS CUI [5,1])
C0205318 (UMLS CUI [5,2])
C0265122 (UMLS CUI [6])
C0268407 (UMLS CUI [7])
Hypotension
Item
5. history of clinically relevant hypotension
boolean
C0020649 (UMLS CUI [1])
Central Nervous System Involvement | Meninges Involvement with Lymphoma | Brain Involvement with Lymphoma
Item
6. cns involvement (meningeal and/or brain involvement by lymphoma)
boolean
C4050309 (UMLS CUI [1])
C0025285 (UMLS CUI [2,1])
C1314939 (UMLS CUI [2,2])
C0024299 (UMLS CUI [2,3])
C0006104 (UMLS CUI [3,1])
C1314939 (UMLS CUI [3,2])
C0024299 (UMLS CUI [3,3])
Malignant Neoplasms Evolving | Exception Skin carcinoma Localized
Item
7. evolving malignancy within 3 years with the exception of localized non-melanomatous skin cancer
boolean
C0006826 (UMLS CUI [1,1])
C0332253 (UMLS CUI [1,2])
C1705847 (UMLS CUI [2,1])
C0699893 (UMLS CUI [2,2])
C0392752 (UMLS CUI [2,3])
HIV Seropositivity
Item
8. hiv positivity
boolean
C0019699 (UMLS CUI [1])
Hepatitis B virus test positive | Exception HBcAb Positive | Exception Hepatitis B surface antigen negative | Exception Hepatitis B Virus Surface Antibody Positive | Exception Hepatitis B Virus Surface Antibody Negative | Exception Hbv DNA Test Negative
Item
9. hbv positivity with the exception of patients with hbvcab +, hbsag -, hbs ab+/- with hbv-dna negative
boolean
C2748184 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C3702086 (UMLS CUI [2,2])
C1514241 (UMLS CUI [2,3])
C1705847 (UMLS CUI [3,1])
C0919711 (UMLS CUI [3,2])
C1705847 (UMLS CUI [4,1])
C0369334 (UMLS CUI [4,2])
C1514241 (UMLS CUI [4,3])
C1705847 (UMLS CUI [5,1])
C0369334 (UMLS CUI [5,2])
C1513916 (UMLS CUI [5,3])
C1705847 (UMLS CUI [6,1])
C1256114 (UMLS CUI [6,2])
C1513916 (UMLS CUI [6,3])
Hepatitis C Virus Positive | Exception Absence Signs Chronic Hepatitis
Item
10. hcv positivity with the exception of patients with no signs of active chronic hepatitis histologically confirmed
boolean
C4330254 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
C0311392 (UMLS CUI [2,3])
C0019189 (UMLS CUI [2,4])
Opportunistic Infections
Item
11. active opportunistic infection
boolean
C0029118 (UMLS CUI [1])
Therapeutic radiology procedure Extensive | Systemic Chemotherapy | Cancer treatment
Item
12. receipt of extensive radiation therapy, systemic chemotherapy, or other antineoplastic therapy
boolean
C1522449 (UMLS CUI [1,1])
C0205231 (UMLS CUI [1,2])
C1883256 (UMLS CUI [2])
C0920425 (UMLS CUI [3])
Exposure to Rituximab
Item
13. exposure to rituximab prior study entry
boolean
C0332157 (UMLS CUI [1,1])
C0393022 (UMLS CUI [1,2])
Investigational New Drugs | Investigational Medical Device
Item
14. have received an experimental drug or used an experimental medical device within 4 weeks before the planned start of treatment. concurrent participation in non-treatment studies is allowed, if it will not interfere with participation in this study.
boolean
C0013230 (UMLS CUI [1])
C2346570 (UMLS CUI [2])
Comorbidity Study Subject Participation Status Excluded | Comorbidity compromises Informed Consent | Mental condition Study Subject Participation Status Excluded | Mental condition compromises Informed Consent
Item
15. any other co-existing medical or psychological condition that would preclude participation in the study or compromise ability to give informed consent
boolean
C0009488 (UMLS CUI [1,1])
C2348568 (UMLS CUI [1,2])
C0332196 (UMLS CUI [1,3])
C0009488 (UMLS CUI [2,1])
C2945640 (UMLS CUI [2,2])
C0021430 (UMLS CUI [2,3])
C3840291 (UMLS CUI [3,1])
C2348568 (UMLS CUI [3,2])
C0332196 (UMLS CUI [3,3])
C3840291 (UMLS CUI [4,1])
C2945640 (UMLS CUI [4,2])
C0021430 (UMLS CUI [4,3])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial